Menu
← Oncology Approval Tracker
FDA DECISION ·
Kisqali / Kisqali Femara Co-Pack
ribociclib with an aromatase inhibitor; ribociclib and letrozole co-pack · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant use of ribociclib with an aromatase inhibitor, including the ribociclib and letrozole co-pack, for adults with HR-positive, HER2-negative stage II or III early breast cancer at high risk of recurrence.
LAMPGEN ANALYSIS
Why it matters
Ribociclib entered the adjuvant setting for a defined high-risk population; the early-stage dose and course differ from metastatic use.
What research teams should watch
Verify stage and recurrence risk in the record, then plan long-term adherence checks, ECGs and blood tests.
PRIMARY RECORDS